Loading
institutionsInstitution
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine
Cornell's medical school and cancer centre in Manhattan, led by immunotherapy pioneer Jedd Wolchok, with major programmes in lymphoma, gastrointestinal and breast cancer.
Also called: Weill Cornell MedicineWeill Cornell Medical CollegeMeyer Cancer CenterNewYork-Presbyterian/Weill Cornell
Overview
The Sandra and Edward Meyer Cancer Center is the cancer centre of Weill Cornell Medicine, Cornell University's medical school on the Upper East Side of Manhattan, and delivers care with NewYork-Presbyterian Hospital. Jedd Wolchok, who led the CheckMate 067 and nivolumab-relatlimab melanoma trials, became its director in 2022. John Leonard's lymphoma programme led AUGMENT; Manish Shah's gastrointestinal oncology group led GLOW in claudin 18.2-positive gastric cancer; and Massimo Cristofanilli directs breast medical oncology and circulating tumour cell research.
Location
New York, NY, US
Type
cancer center · Cornell University
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#428 · 12 points (0 Newsweek + 0 NCI + 12 from 6 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Weill Cornell Medicine, including child institutions. 1,217 works · 17,939 citations · 70% open access · 8% clinical trials · 2% reviews.
Oncology works per year
2422022
3012023
2612024
2532025
1602026
Most works
- Olivier Elemento51 works
- Rulla M. Tamimi50 works
- Massimo Cristofanilli39 works
- Silvia Chiara Formenti33 works
- Jedd D. Wolchok33 works
- Nasser Khaled Altorki31 works
- Shari R. Lipner30 works
- Carolina Reduzzi29 works
- Lisa A. Newman27 works
- Shoshana M. Rosenberg27 works
Most cited
- Immunotherapy
- Lymphoma
- Gastrointestinal oncology
- Breast oncology
Jedd D. Wolchok
Meyer Director, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine
Melanoma immunotherapyCheckpoint inhibitor combinationsImmune-related response criteria
Led CheckMate 067, the trial whose ten-year data showed half of advanced melanoma patients on nivolumab plus ipilimumab are alive.
John P. Leonard
Haematologist-oncologist, Weill Cornell Medicine
Follicular lymphomaMarginal zone lymphomaImmunomodulatory therapy
New York lymphoma specialist who led AUGMENT, the trial that established lenalidomide plus rituximab as a chemotherapy-free option for relapsed follicular and marginal zone lymphoma.
Manish A. Shah
Gastrointestinal medical oncologist, Weill Cornell Medicine
Gastric cancerClaudin 18.2Molecular subtypes of gastric cancer
New York oncologist who was lead author of GLOW, one of the two trials that established zolbetuximab, the first drug aimed at claudin 18.2, for stomach cancer.
Massimo Cristofanilli
Professor of Medicine and Director of Breast Medical Oncology, Weill Cornell Medicine
Metastatic breast cancerCirculating tumour cellsCDK4/6 inhibitors
Showed that counting tumour cells in blood predicts survival in breast cancer and co-led PALOMA-3, which brought palbociclib to endocrine-resistant disease.
Similar pages
- Key paperAUGMENT: lenalidomide plus rituximab versus rituximab alone in relapsed indolent lymphoma
Shares John P. Leonard, Follicular lymphoma.
- TrialAUGMENT
Shares John P. Leonard, Follicular lymphoma.
- PersonClifford A. Hudis
Shares Memorial Sloan Kettering Cancer Center, HR-positive / HER2-negative breast cancer.
- Key paperRibas and Wolchok 2018: cancer immunotherapy using checkpoint blockade
Shares Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center.
- PersonPaul B. Chapman
- PersonMonica Morrow
Shares Memorial Sloan Kettering Cancer Center, HR-positive / HER2-negative breast cancer.
- Key paperCheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma
Shares Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, Melanoma.
- PersonShanu Modi
Shares Memorial Sloan Kettering Cancer Center, HR-positive / HER2-negative breast cancer.